Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Pentaxim

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Background: The live, attenuated, tetravalent dengue vaccine (CYD-TDV) is licensed in a number of dengue endemic countries for… Expand
2017
2017
BACKGROUND Vaccines have greatly contributed to the control of vaccine-preventable diseases and to human development. Efforts by… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
2012
2012
ObjectiveTo evaluate the immunogenicity and safety of a pentavalent (diphtheria, tetanus, acellular pertussis, inactivated… Expand
  • table I
  • table II
  • table III
2011
2011
OBJECTIVE To assess the immunogenicity and safety data for a pentavalent combination vaccine containing acellular pertussis… Expand
  • figure 1
  • table II
  • table I
  • figure 2
  • table III
2011
2011
Background and Aims: Assessment of a new, fully liquid, investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine (Hexaxim, Sanofi… Expand
2011
2011
  • Rong Cheng Li, Feng Xiang Li, +16 authors E. Ortiz
  • Vaccine
  • 2011
  • Corpus ID: 205584758
The aim was to demonstrate the immunogenicity and safety of a DTaP-IPV//PRP-T combined vaccine (Pentaxim(®)) compared to… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
2011
2011
This study assessed the antibody persistence, and the immunogenicity and safety of a booster dose of a DTaP-IPV//PRP∼T (Pentaxim… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 3
2010
2010
The objective of this study was to evaluate the immunogenicity and safety of a pentavalent vaccine (Pentaxim) containing… Expand
2009
2009
This study assessed the booster immune response to a pentavalent combination vaccine containing diphtheria, tetanus, acellular… Expand
2008
2008
Background: Data on the immunogenicity and safety of acellular pertussis-based combination vaccines when given in the WHO… Expand